{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:07:49Z","timestamp":1793725669014,"version":"4.6.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Research & Clinical Practice"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.orcp.2025.01.011","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T12:46:00Z","timestamp":1738932360000},"page":"77-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system \u2013 A disproportionality analysis"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9336-5055","authenticated-orcid":false,"given":"Marina","family":"Azab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pasina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.orcp.2025.01.011_bib1","doi-asserted-by":"crossref","first-page":"994","DOI":"10.3390\/ph16070994","article-title":"Is there a risk for semaglutide misuse? Focus on the food and drug administration\u2019s FDA adverse events reporting system (FAERS) pharmacovigilance dataset","volume":"16","author":"Chiappini","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.orcp.2025.01.011_bib2","unstructured":"Impact of Semaglutide and Dulaglutide Shortages [Internet]. Australian Journal of General Practice. Available from: \u3008https:\/\/www1.racgp.org.au\/ajgp\/2024\/january-february\/impact-of-semaglutide-and-dulaglutide-shortages\u3009. [cited 2024 Jul 23]."},{"key":"10.1016\/j.orcp.2025.01.011_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol [Internet]"},{"key":"10.1016\/j.orcp.2025.01.011_bib4","unstructured":"Liminga UW, Martirosyan L . Pharmacovigilance risk assessment committee (PRAC)."},{"key":"10.1016\/j.orcp.2025.01.011_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - inspection of U.S. American Adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.orcp.2025.01.011_bib6","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, Ponti FD, Poluzzi E, Raschi E, Data Mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). Data Mining Applications in Engineering and Medicine [Internet]. IntechOpen; 2012. Available from: https:\/\/www.intechopen.com\/chapters\/38579. [cited 2023 Nov 6].","DOI":"10.5772\/50095"},{"key":"10.1016\/j.orcp.2025.01.011_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.orcp.2025.01.011_bib8","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/11635890-000000000-00000","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection","volume":"26","author":"H\u00f6lscher","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.orcp.2025.01.011_bib9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2337\/db15-0443","article-title":"Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes","volume":"65","author":"Hern\u00e1ndez","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.orcp.2025.01.011_bib10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2147\/CLEP.S456170","article-title":"Semaglutide (Ozempic\u00ae) Use in Denmark 2018 Through 2023 - user trends and off-label prescribing for weight loss","volume":"16","author":"Mailhac","year":"2024","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.orcp.2025.01.011_bib11","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/d41586-024-01091-8","article-title":"Obesity drugs aren\u2019t always forever. What happens when you quit?","volume":"628","author":"Prillaman","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.orcp.2025.01.011_bib12","unstructured":"DeSilver D. As obesity rates rise in the U.S. and worldwide, new weight-loss drugs surge in popularity [Internet]. Pew Research Center; 2024. Available from: \u3008http:\/\/www.pewresearch.org\/short-reads\/2024\/03\/21\/as-obesity-rates-rise-in-the-us-and-worldwide-new-weight-loss-drugs-surge-in-popularity\/\u3009[cited 2024 Jul 23]."}],"container-title":["Obesity Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X25000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X25000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:11:37Z","timestamp":1740139897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871403X25000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1871403X25000171"],"URL":"https:\/\/doi.org\/10.1016\/j.orcp.2025.01.011","relation":{},"ISSN":["1871-403X"],"issn-type":[{"value":"1871-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide: Nonarteritic Anterior Ischemic Optic Neuropathy in the FDA adverse event reporting system \u2013 A disproportionality analysis","name":"articletitle","label":"Article Title"},{"value":"Obesity Research & Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.orcp.2025.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}